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AbstrACt
Introduction Insomnia is a prevalent sleep disorder that 
negatively affects quality of life. Multicomponent cognitive- 
behavioural therapy (CBT) is the recommended treatment 
but access remains limited, particularly in primary care. 
Sleep restriction therapy (SRT) is one of the principal active 
components of CBT and could be delivered by generalist 
staff in primary care. The aim of this randomised controlled 
trial is to establish whether nurse- delivered SRT for 
insomnia disorder is clinically and cost- effective compared 
with sleep hygiene advice.
Methods and analysis In the HABIT (Health- professional 
Administered Brief Insomnia Therapy) trial, 588 
participants meeting criteria for insomnia disorder will be 
recruited from primary care in England and randomised 
(1:1) to either nurse- delivered SRT (plus sleep hygiene 
booklet) or sleep hygiene booklet on its own. SRT will 
be delivered over 4 weekly sessions; total therapy time 
is approximately 1 hour. Outcomes will be collected at 
baseline, 3, 6 and 12 months post- randomisation. The 
primary outcome is self- reported insomnia severity using 
the Insomnia Severity Index at 6 months. Secondary 
outcomes include health- related and sleep- related 
quality of life, depressive symptoms, use of prescribed 
sleep medication, diary and actigraphy- recorded sleep 
parameters, and work productivity. Analyses will be 
intention- to- treat. Moderation and mediation analyses 
will be conducted and a cost- utility analysis and process 
evaluation will be performed.
Ethics and dissemination Ethical approval was granted 
by the Yorkshire and the Humber - Bradford Leeds 
Research Ethics Committee (reference: 18/YH/0153). We 
will publish our primary findings in high- impact, peer- 
reviewed journals. There will be further outputs in relation 
to process evaluation and secondary analyses focussed 
on moderation and mediation. Trial results could make the 
case for the introduction of nurse- delivered sleep therapy 
in primary care, increasing access to evidence- based 
treatment for people with insomnia disorder.
trial registration number ISRCTN42499563
IntroduCtIon
Insomnia disorder is characterised by 
persistent problems with sleep initiation and 
maintenance, significantly impairing quality 
of life.1–3 Persistent insomnia affects approx-
imately 10% of the adult population4 and is 
a risk factor for several mental and physical 
health problems, particularly depression and 
cardiometabolic disease.5 6 Insomnia is also an 
expensive condition, associated with substan-
tial direct and indirect costs; chiefly reflecting 
increased healthcare utilisation, work- related 
absenteeism, reduced work productivity and 
elevated accident risk.7–9
Insomnia is treatable. The principal treat-
ment options are hypnotic medication 
and cognitive behavioural therapy (CBT). 
The former is indicated for short- term use 
only, while the latter is the recommended 
first- line treatment and has been shown to 
strengths and limitations of this study
 ► This multicentre randomised controlled trial will re-
cruit 588 participants and will be the largest trial of 
sleep restriction therapy (SRT) for insomnia.
 ► This study will test whether brief, nurse- delivered 
SRT in primary care is clinically and cost- effective.
 ► The control group will be provided with a sleep hy-
giene booklet while the SRT arm will receive both 
nurse- delivered SRT and a sleep hygiene booklet.
 ► The primary outcome is self- reported insomnia se-
verity while secondary outcomes include actigraphy- 
defined sleep, use of sleep medication, quality of life 
and depressive symptoms.
 ► Owing to the nature of the intervention participants 
will not be blind to treatment allocation.
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engender sustained improvement in self- reported sleep 
and insomnia severity.10 Despite national and interna-
tional clinical guidelines recommending CBT,11–13 access 
is almost non- existent in routine care across many health 
systems. In the absence of available treatment, general 
practitioners (GPs) are limited to administering sleep 
hygiene guidelines, hypnotics and (off- label) sedative 
antidepressants;14 15 yet none are evidence- based for 
persistent insomnia12 16 and hypnotics have well- defined 
side- effects.4 Barriers to wide- scale adoption of CBT in 
routine healthcare relate to limited training, expertise 
and funding. A major development in the insomnia field, 
therefore, has been the dismantling of multicomponent, 
multisession CBT into brief and focussed treatment pack-
ages17 and the training of non- specialists to deliver such 
therapies.18–20
Sleep restriction therapy (SRT) has emerged as one of 
the primary active ingredients within multicomponent 
CBT. The therapy involves restricting and standardising 
a patient’s time in bed with the aim of increasing homeo-
static sleep pressure, over- riding cognitive and physio-
logical arousal and strengthening circadian regulation 
of sleep.21 Tailored prescription of bed and rise times 
over several weeks leads to improved sleep consolidation 
and reduction in insomnia severity. Its short length and 
simplicity renders SRT ideally suited for delivery by gener-
alist staff in primary care.
A systematic review of trials comparing single- 
component SRT to waitlist control or sleep hygiene 
advice found medium- to- large effects on sleep conti-
nuity measures.22 Moreover, recent trials suggest SRT 
may be as effective as multicomponent CBT.23 24 One 
primary care trial compared brief SRT (delivered by one 
GP) with sleep hygiene advice.25 The participants were 
highly selected so that they were free from comorbidity 
or medication use. SRT significantly reduced insomnia 
severity at 6 months (Cohen’s d=0.54). While this was an 
important first study, a pragmatic trial in primary care 
testing a scalable model of treatment delivery is clearly 
required.
We have developed a brief SRT protocol based on (1) 
our extensive research using multicomponent CBT18–20 
and (2) systematic examination of the patient experience 
of SRT.26 We aim to test whether brief SRT (alongside 
sleep hygiene advice) is both clinically and cost- effective, 
relative to sleep hygiene advice on its own. We have chosen 
practice nurses instead of GPs based on previous successful 
trial experience with this professional group18–20 and with 
cost- effectiveness and scalability in mind. Practice nurses 
are increasingly involved in chronic disease management 
(where sleep disturbance is a common comorbidity) and 
the delivery of brief behavioural interventions in primary 
care.27 While previous studies in UK primary care show 
multicomponent CBT to be effective when delivered 
by nurses,18 19 counsellors28 or through self- help CBT 
booklets,29 there has been no large- scale evaluation of 
the clinical and cost- effectiveness of a brief and scalable 
behavioural intervention.
study objectives
The primary objective of the HABIT (Health- professional 
Administered Brief Insomnia Therapy) trial is to estab-
lish whether nurse- delivered SRT(+sleep hygiene (SH)) 
for insomnia disorder in primary care improves insomnia 
more than SH alone. We hypothesise that participants 
allocated to SRT(+SH) will demonstrate lower insomnia 
severity at 6 months post- randomisation compared with 
those allocated to SH alone.
Our secondary hypotheses are as follows:
1. Compared with SH, participants allocated to SRT(+SH) 
will report improvements in health- related quality of 
life, sleep- related quality of life, depressive symptoms, 
work productivity, pre- sleep arousal and sleep effort (at 
3, 6 and 12 months).
2. Compared with SH, participants allocated to SRT(+SH) 
will demonstrate improvements in sleep parameters 
(diary and actigraphy- recorded) and report a reduc-
tion in use of sleep- promoting medication (6 and 12 
months).
3. The effect of SRT(+SH) on insomnia severity will be 
mediated via reduction in sleep effort and pre- sleep 
arousal, consistent with theoretical models.21
Other objectives:
4. To establish whether nurse- delivered SRT(+SH) for in-
somnia disorder in primary care is cost- effective com-
pared with SH, from National Health Service (NHS) 
and societal perspectives.
5. To undertake a process evaluation to understand inter-
vention delivery, fidelity and acceptability.
6. To test whether insomnia phenotype moderates clini-
cal benefit obtained from SRT(+SH). One prominent 
model posits that participants with objective short sleep 
duration are less likely to experience improvement in 
insomnia relative to those with normal sleep duration.5 
We will examine whether actigraphy- defined sleep du-
ration (<6 hours vs ≥6 hours) at baseline moderates the 
effect of SRT on clinical outcomes (at 6 months)
7. To test whether SRT adherence mediates degree of 
clinical change (Insomnia Severity Index (ISI)) from 
baseline to 3 months, and from baseline to 6 months.
MEthods And AnAlysIs
trial design
This is a pragmatic, multicentre, individually randomised, 
parallel group, superiority trial to test whether nurse- 
delivered SRT(+SH), compared with SH alone, reduces 
insomnia severity. Both groups will receive treatment as 
usual without restriction. Participants will be recruited 
from general practices across three regions in the UK 
(Thames Valley, Greater Manchester and Lincolnshire). 
Assessments will take place at baseline, 3, 6 and 12 months 
post- randomisation (see figure 1 for trial flow). The trial 
is prospectively registered with the ISRCTN. There is a 
Trial Steering Committee and Data Monitoring and 
Ethics Committee, both comprised of majority indepen-
dent members.
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Figure 1 Trial flow. SH,sleep hygiene; SRT, sleep restriction 
therapy.
Participants and recruitment
We aim to recruit participants aged 18 years and above 
in primary care practices who meet criteria for insomnia 
disorder. Since insomnia is not commonly coded within 
practice records we will search records for broad sleep- 
related terms, sleep- related medications and associated 
conditions to identify those most likely to be eligible, 
while applying exclusionary diagnoses. We will send 
invitations to identified individuals. We will also identify 
potential participants through (a) direct face- to- face GP 
referral (participants will be provided with an informa-
tion sheet and contact details for the research team), (b) 
placing posters in practices (containing study contact 
details) and (c) posting study adverts on the Internet (eg, 
practice websites, Facebook).
Participants will be screened for eligibility over the 
phone by the research team, or through self- completion 
of an online questionnaire. The inclusion criteria are as 
follows: (a) participant is willing and able to give informed 
consent for participation, (b) screen positive for insomnia 
symptoms on the Sleep Condition Indicator30 and meet 
DSM-5 (Diagnostic and Statistical Manual of Mental Disor-
ders, Fifth Edition) criteria for insomnia disorder, (c) 
self- reported sleep efficiency <85% over the past month, 
(d) age ≥18 years and (e) able to attend appointments 
during baseline and 4- week intervention (both face- to- 
face at the practice and over the phone) and adhere to 
study procedures.
Exclusions will be limited principally to conditions 
which may be contraindicated for SRT, or render SRT 
inappropriate or ineffective: (a) pregnant/pregnancy 
planning in the next 6 months; (b) additional sleep 
disorder diagnosis (eg, restless legs syndrome, obstruc-
tive sleep apnoea, narcolepsy) or ‘positive’ screen on 
screening questionnaire;31 (c) dementia or mild cogni-
tive impairment; (d) diagnosis of epilepsy, schizophrenia 
or bipolar disorder; (e) current suicidal ideation with 
intent32 or attempted suicide within past 2 months; (f) 
currently receiving cancer treatment or planned major 
surgery during treatment phase; (g) night, evening, 
early morning or rotating shift- work; (h) currently 
receiving psychological treatment for insomnia from 
a health professional or taking part in an online treat-
ment programme for insomnia and (i) life expectancy 
of <2 years. On completion of screening, eligible partic-
ipants will be invited to a baseline appointment with a 
member of the research team where they will give written 
informed consent (see appendices), complete baseline 
questionnaires (see assessments section) and be provided 
with a sleep diary and actigraph watch for the following 
week. Participants will return the completed diary and 
actigraph watch to the research team via postal mail.
Interventions
Sleep hygiene
Usual care for persistent insomnia typically involves sleep 
hygiene advice, repeat hypnotic prescription and use of 
sedative antidepressants or antihistamines.14 15 For those 
aged 55+ years, melatonin may also be prescribed for 
insomnia, consistent with English guidelines from the 
National Institute for Health and Care Excellence (NICE; 
13). Evidence shows that access to and awareness of CBT 
for insomnia in primary care is very limited.14
Since NICE recommends that individuals with 
persistent insomnia should receive sleep hygiene advice, 
it is likely that some participants will have been exposed to 
such information in the past. Therefore, to avoid bias, all 
participants in both arms will be provided with the same 
standardised sleep hygiene information. We will provide a 
booklet comprising standard behavioural guidance about 
lifestyle and environmental factors associated with sleep 
and sleeplessness.33 Participants randomised to the SH 
arm will be sent their booklet via email or post.
Consistent with the requirements of a pragmatic trial, 
there will be no restrictions on usual care for both groups. 
In this way, the trial represents a comparison of SRT(+SH) 
(+treatment as usual (TAU)) versus SH(+TAU), permit-
ting clear judgement to be made regarding the relative 
clinical utility of SRT in routine clinical practice.
Sleep restriction therapy
Participants in the intervention arm will be offered nurse- 
delivered insomnia therapy in the form of SRT, a manual-
ised behavioural intervention. See online supplementary 
table 1 for a detailed description of the intervention 
according to the template for intervention description 
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and replication (TIDieR) checklist.34 We will initially aim 
to train practice nurses to deliver SRT but in order to over-
come scheduling issues that may arise, or limitations on 
practice capacity, we will also train research nurses from 
clinical research networks to support delivery. Nurses will 
receive a 4 hour training session on insomnia and the 
delivery of SRT as well as access to supporting resources 
(eg, recorded video clips and a list of frequently asked 
questions and answers in relation to treatment delivery). 
Trained nurses will deliver manualised SRT over four 
brief, weekly sessions (total contact time=approximately 
1 hour 5 mins). In session 1 the nurse will work through 
slides with the participant to introduce the rationale 
for SRT alongside a review of sleep diaries, selection of 
bed and rise times, management of daytime sleepiness 
(including implications for driving) and discussion of 
barriers/facilitators to implementation. Participants 
will also be provided with a booklet to read in their own 
time, which includes information on theory underlying 
SRT and a list of sleep hygiene guidelines (identical to 
those provided to the control arm). Participants will be 
provided with diaries and sleep efficiency calculation 
grids to support implementation of SRT instructions and 
permit weekly review of progress. Sessions 2, 3 and 4 will 
be brief sessions (10 to 15 min) to review progress, trou-
bleshoot any difficulties and advise on adaptation of the 
sleep schedule.35 Sessions 1 and 3 will be in- person at the 
practice while sessions 2 and 4 will be over the phone.
randomisation and blinding
Following completion of baseline assessments participants 
will be randomised (1:1) to SRT(+SH) or SH using a fully 
validated web- based randomisation programme (Sorti-
tion), with a non- deterministic minimisation algorithm 
to balance region (Thames Valley, Lincolnshire, Greater 
Manchester), use of prescribed sleep promoting medica-
tion (yes/no), age (18 to 65 years vs >65 years), sex, base-
line ISI36 score (<22 vs 22 to 28) and depression symptom 
severity (Patient Health Questionnaire-9 (PHQ-9)37 score 
<10 vs 10 to 27) across the two groups. Members of the 
research team will inform participants of their allocation.
This is an open- label study and therefore both partici-
pants and nurses will be aware of allocation. The partic-
ipant information sheet will inform participants that 
the study compares two different sleep intervention 
programmes but will not reveal the study hypothesis. 
Treatment providers (nurses) will not be involved in the 
collection of trial outcomes. Outcomes (questionnaires, 
diaries and actigraphy) are self- completed, remotely, by 
participants. It will be impractical to blind the research 
team however actigraph data will be scored by a sleep 
researcher blind to group allocation and the trial statisti-
cians will remain blind to group allocation.
Assessments
The primary outcome is insomnia severity assessed by 
the ISI,36 and will be measured at baseline, 3, 6 and 12 
months post- randomisation. Secondary outcomes will 
similarly be measured at all four timepoints and they are 
health- related quality of life (ShortForm 36 Question-
naire (SF-36); 38), sleep- related quality of life (Glasgow 
Sleep Impact Index (GSII; 3)), depressive symptoms 
(PHQ-9; 37), work productivity and activity impairment 
(Work Productivity and Activity Impairment question-
naire (WPAI); 39), sleep effort (Glasgow Sleep Effort Scale 
(GSES); 40) and arousal (Pre- Sleep Arousal Scale (PSAS); 
41). Questionnaires will be completed online or on paper, 
depending on participant preference. Self- reported sleep 
and use of sleep medication will be captured over 7 days 
using the consensus sleep diary42 collected at baseline, 
6 and 12 months. The consensus sleep diary will also be 
completed by the SRT group during the 4- week inter-
vention phase. Actigraphy- defined sleep (CamNtech 
Ltd., MotionWatch 8) will be measured at baseline, 6 
and 12 months. A modified version of the Client Service 
Receipt Inventory (CSRI; 43) and the EuroQol Question-
naire (EQ- 5D- 3L; 44) will be administered at baseline, 3, 
6 and 12 months to inform the cost- effectiveness evalu-
ation. Participants will receive vouchers for completion 
of outcomes at each assessment point (vouchers = £5 at 
baseline, £10 at 3 months, £15 at 6 months and £10 at 
12 months). A summary of outcomes in relation to study 
objectives can be found in table 1.
Process evaluation
Consistent with Medical Research Council guidance for 
trials of complex interventions we will conduct a process 
evaluation.45 The aim of the process evaluation is to 
explore nurse- delivered SRT in the primary care setting 
by examining implementation, mechanisms of impact 
and contextual factors that facilitate or impede interven-
tion delivery. This will complement the outcomes eval-
uation, helping to understand the trial results through 
exploring:
i. Nurse perceptions of SRT, including training and 
support.
ii. Fidelity of intervention delivery by nurses.
iii. Whether participants in the control group also re-
ceive SRT (ie, contamination).
iv. The participant experience of SRT, including re-
flections on implementing the sleep schedule and 
perceptions of benefit, as well as any unexpected 
consequences.
v. Whether level of adherence mediates degree of clin-
ical improvement.
vi. Views of primary care staff in relation to the imple-
mentation of SRT beyond the context of the trial.
In order to capture experiences and perceptions of 
SRT semi- structured interviews will be conducted by the 
research team with a sample of practice nurses (n=15), 
trial participants (n=15) and practice managers or GPs 
(n=15) across the three study sites. Interview participants 
will be invited from five practices from each of the three 
trial recruitment centres. The practices will be selected 
to reflect a range of practice types (eg, based on prac-
tice size, or membership of a consortium) and, for each 
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Table 1 Objectives and outcome measures
Objectives Outcome measures
Timepoint(s) of evaluation of this 
outcome measure
Primary objective:
To compare the effect of SRT+SH vs 
SH on insomnia severity
Self- rated insomnia severity using the ISI 
questionnaire
Baseline, 3, 6 and 12 months post- 
randomisation. Primary outcome is at 6 
months.
Secondary objectives:
To compare the effect of SRT+SH vs 
SH on HRQoL
Self- rated HRQoL using the SF-36 
questionnaire (total score, MCS, PCS)
Baseline, 3, 6 and 12 months post- 
randomisation.
To compare the effect of SRT+SH vs 
SH on subjective sleep
Subjective sleep recorded over 7 nights 
using the CSD (SOL; WASO; SE; TST; SQ)
Baseline, 6 and 12 months post- 
randomisation.
To compare the effect of SRT+SH vs 
SH on objective estimates of sleep
Actigraphy- defined sleep over 7 nights
(SOL; WASO; SE; TST)
Baseline, 6 and 12 months post- 
randomisation.
To compare the effect of SRT+SH vs 
SH on (1) patient- generated quality of 
life, (2) depressive symptoms, (3) work 
productivity, (4) hypnotic medication 
use, (5) use of other prescribed sleep- 
promoting medications and (6) pre- 
sleep arousal and sleep effort
1. Self- rated quality of life using the GSII 
(ranks 1, 2, 3)
2. Self- rated depressive symptoms severity 
using the PHQ-9
3. Self- rated WPAI questionnaire
4. Use of prescribed hypnotics (quantified 
from 7 day diary)
5. Use of other prescribed sleep- promoting 
medications (quantified from 7 day diary)
6. Self- rated arousal and sleep effort using 
the PSAS and GSES
Baseline, 3, 6 and 12 months post- 
randomisation.
Medication use will be quantified from 
diaries at baseline, 6 and 12 months 
post- randomisation.
To compare the incremental cost- 
effectiveness of SRT+SH over 
SH, from both NHS and societal 
perspectives
Trial records (time and number of nurse- 
led appointments), practice records* 
(medications), CSRI, ISI, WPAI, EQ- 5D- 3L
Baseline, 3, 6 and 12 months post- 
randomisation.
*Baseline and 12 months only
To undertake a process evaluation to 
explain trial results and understand 
intervention delivery, fidelity and 
acceptability.
Semi- structured interviews with (1) trial 
participants, (2) nurses, (3) GPs or practice 
managers.
Throughout the trial.
Moderator analysis:
Test whether objective short sleep 
duration at baseline (<6 hours vs 
≥6 hours) moderates the effect of SRT 
on clinical outcomes (at 6 months)
Actigraphy, ISI, GSII, SF-36 Baseline and 6 months.
Mediator analysis:
Test whether group difference on the 
ISI (6 months) is mediated by change 
in PSAS and GSES assessed at month 
3
Test whether SRT adherence mediates 
degree of clinical change on the ISI
ISI, PSAS, GSES
Sleep diary during intervention phase, ISI
  Baseline, 3 and 6 months.
To compare the number of specified 
adverse events between the groups
Questionnaire Baseline, 3, 6 and 12 months.
CSD, Consensus Sleep Diary; CSRI, client service receipt inventory; EQ- 5D- 3L, EuroQol 5 Dimensions 3 Levels Questionnaire; GPs, general 
practitioners; GSES, Glasgow Sleep Effort Scale; GSII, Glasgow Sleep Impact Index; HRQoL, health- related quality of life; ISI, Insomnia 
Severity Index; MCS, mental component summary score; NHS, National Health Service; PCS, physical component summary score; PHQ-9, 
patient health questionnaire; PSAS, Pre- Sleep Arousal Scale; SE, sleep efficiency; SF-36, Short Form 36 Questionnaire; SH, sleep hygiene; 
SOL, sleep- onset latency; SQ, sleep quality; SRT, sleep restriction therapy; TST, total sleep time; WASO, wake time after sleep onset; WPAI, 
work productivity and activity impairment questionnaire.
selected practice, one nurse, one trial participant and one 
GP or practice manager will be interviewed. These will be 
in- depth semi- structured telephone, Skype, or face- to- face 
interviews lasting 30 to 60 min using separate interview 
schedules for each group. Consent process and interviews 
will be digitally audio recorded and transcribed verbatim. 
Professionals will be asked about their working role in 
relation to delivering the SRT intervention. Participant 
interviews will take place after the intervention phase. 
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Participants will receive a £10 voucher for interview 
participation.
To enable fidelity assessment, all in- person SRT sessions 
will be recorded (if participants consent). A sample 
of these sessions will be rated by a trained member of 
the research team using a bespoke rating scale. We will 
monitor potential for control group contamination (ie, 
SH participants accessing SRT via the trained practice 
nurse) through questionnaire43 completion at 3 and 6 
months follow- up. SRT engagement will be measured 
with respect to number of treatment sessions attended, 
while adherence to therapeutic instructions (prescribed 
bed and rise times) will be quantified from sleep diaries 
recorded during the 4- week intervention phase.
sample size
To detect a difference on the ISI of 1.35 points (SD=4.50) 
between the group means of SRT+SH and SH, with a 
power of 90% at 5% level of significance (two- sided), 
235 participants would be required in each treatment 
group. This equates to a standardised effect size of 0.3. 
The SD was based on the results from the primary care 
evaluation of SRT conducted by Falloon and colleagues.25 
Accounting for 20% attrition the total number of partic-
ipants required to be recruited is 588 (294 per group). 
Should attrition be higher, at 25% or 30%, the total 
number of participants required would be 628 (314 per 
group) or 672 (336 per group), respectively.
Most CBT evaluations show large effects on the ISI46 but 
these studies have small samples, are tightly controlled 
and recruit participants from the community, who are 
generally free from comorbidity or medication. Given 
that our study is a pragmatic trial, across multiple NHS 
sites, with a varied group of insomnia patients (repre-
senting clinical reality), we would anticipate a lower 
effect size for the ISI. Falloon and colleagues25 recruited 
a highly selected group of patients and delivered treat-
ment via one research GP, observing an effect size of 0.54 
at 6 months on the ISI. Thus, powering the study for a 
moderate standardised effect size of 0.3 is conservative 
and appropriate given our design features. The sample 
size will also allow us to detect an average difference of 
2.7 points (SD=9.047) on the SF-36 (health- related quality 
of life), our important secondary outcome, at 90% power 
and 5% level of significance.
For the interviews we aim to recruit 15 participants, 
consistent with our previous experience of Framework 
analysis48 and guidelines recommending that a minimum 
of 12 interviews are needed to achieve data saturation.49
Adverse events
The likelihood of serious adverse events (SAEs) occur-
ring due to treatment is low since neither CBT/SRT nor 
sleep hygiene advice have been reported to cause them. 
We define SAEs as any untoward medical occurrence 
that either: (a) results in death, (b) is life- threatening, 
(c) requires inpatient hospitalisation or prolongation 
of existing hospitalisation, (d) results in persistent or 
significant disability/incapacity or (d) consists of a 
congenital anomaly or birth defect. Nurse therapists and 
participants will be prompted to self- report SAEs. Along 
with self- reporting of SAEs, we will also use responses 
on the CSRI43—which includes questions on hospitalisa-
tions—to follow- up participants who report being hospi-
talised. We will record planned hospital admissions at 
baseline and, when they occur, these will not be counted 
as SAEs. SAEs will be assessed for severity, seriousness and 
relatedness to study procedures by a medically qualified 
member of the team. SAEs will be reported after date of 
randomisation until either the date of trial withdrawal or 
6- month follow- up completion, whichever is earlier.
Because implementation of SRT may be associated with 
increased sleepiness we will also record falls, accidents 
(including road- traffic accidents and work- related inju-
ries) and near- miss driving incidents alongside outcomes 
at baseline, 3, 6 and 12 months post- randomisation and 
report these by randomised group.
Analysis plan
Statistical analysis
The primary statistical analysis will be carried out on 
the basis of intention- to- treat (ITT). We will endeavour 
to obtain full follow- up data on every participant to 
allow full ITT analysis, but we will inevitably experience 
the problem of missing data due to withdrawal, loss to 
follow- up or non- response to some questionnaire items. 
The results from the trial will be prepared as compara-
tive summary statistics with 95% CIs. All the tests will be 
performed at a 5% two- sided significance level. The study 
results will be reported in accordance with the Consoli-
dated Standards of Reporting Trials guidelines.50 A full 
detailed statistical analysis plan will be prepared and final-
ised before data collection is complete.
A three- level mixed effect linear model based on an 
unstructured covariance matrix will be fitted to the 
primary outcome data (ISI at 6 months), utilising 3, 6 
and 12 month timepoints. Practice and participant will 
be included as random effects. Fixed effects will include 
randomised group, baseline ISI score, stratification vari-
ables, time and a time by randomised group interaction 
term to allow estimation of treatment effect at each 
timepoint.
Missing data will be reported (alongside reasons for 
missingness where available) and the missing data pattern 
will be explored, though the mixed effects model implic-
itly accounts for data missing at random. Standard residual 
diagnostics will be assessed for the appropriateness of the 
model and if assumptions are violated we will consider 
alternative non- parametric approaches for the main anal-
ysis. Continuous secondary outcomes will be analysed 
using the same method. Secondary outcomes that are 
binary (eg, zero hypnotic use over 7 days) or count vari-
ables (eg, number of nights hypnotic- free over 7 nights) 
will be analysed using generalised linear mixed effect 
models with appropriate link function. We will undertake 
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prespecified subgroup analysis of the primary outcome by 
actigraphy- defined sleep duration at baseline (<6 hours vs 
≥6 hours). Mediation analyses will be conducted using the 
approach of Baron and Kenny51 but will follow the adap-
tation in Freeman et al52 which makes use of linear mixed 
effects models. This will allow us to determine the extent 
to which the 3- month arousal outcomes (PSAS, GSES) 
mediate the 6- month ISI outcome. All models will include 
the baseline assessments of the mediator and ISI as covari-
ates. A complier- average causal effect (CACE) analysis of 
the primary outcome will be carried out to determine the 
impact of the treatment effect when accounting for non- 
compliance of the allocated intervention (ie, SRT session 
attendance). CACE is a measure of the causal effect of an 
intervention for participants who received it as intended 
by the original group allocation. We will also explore the 
effect of level of adherence to prescribed bed and rise 
times (captured by sleep diaries) on the primary outcome 
in those who received SRT.
Economic analysis
A within- trial economic evaluation alongside the RCT will 
estimate the incremental cost- effectiveness of SRT+SH 
over SH, from both NHS and societal perspectives. In 
our economic analyses we will adopt the UK NHS and 
personal social services perspective, consistent with NICE 
guidelines.53 Additional analyses will examine costs from 
a societal perspective, quantifying productivity losses in 
relation to absenteeism and presenteeism.
From trial records we will quantify participants’ atten-
dance at SRT sessions and hence nurse time and also 
assess the resources used in training. We will collect data 
on healthcare usage through GP records (medication 
use) and a self- reported version of CSRI.43 The Personal 
Social Services Research Unit Costs of Health and Social 
Care54 and NHS Reference Costs55 will be used to apply 
national average unit costs to service utilisation and 
construct a cost profile per participant. Productivity will 
be quantified from the WPAI questionnaire39, and costed 
using the human capital approach.
Analysis of the ISI (assessed at baseline, 3, 6 and 12 
months) will indicate the incremental cost per unit 
change in self- reported insomnia severity. As recom-
mended by NICE, cost- utility analysis will examine incre-
mental quality- adjusted life- years (QALYs). This will be 
achieved through collecting data on health status using 
the EQ- 5D- 3L44 at baseline, 3, 6 and 12 months, and 
calculating the area under the curve. An incremental 
cost- effectiveness ratio will be calculated using costs- 
per- QALY with a 12- month time horizon. We will add a 
sleep dimension56 to the standard EQ- 5D- 3L allowing 
us to examine, in exploratory analysis, the relationship 
between sleep bolt- on responses and other measures of 
insomnia severity, to identify whether the sleep question 
correlates with other measures of sleep satisfaction and 
self- reported health. Probabilistic and deterministic sensi-
tivity analysis will be conducted to characterise the uncer-
tainty around the cost- effectiveness estimates.
Qualitative analysis
We will use a Framework approach57 for qualitative data 
analysis supported by QSR NVivo (V.11), with the frame-
work based on the main areas of implementation, mech-
anisms of impact and contextual factors together with 
the more detailed issues that arise from these. Analysis 
will occur as the interviews are transcribed and this anal-
ysis will allow schedules and data collection to be further 
developed. We will analyse qualitative process data prior 
to knowing trial outcomes to avoid biassed interpretation.
Patient and public involvement
Four people from the Healthier Ageing Public and 
Patient Involvement group, University of Lincoln, 
read and provided detailed comments on the original 
grant proposal, helping to shape key methodological 
choices (eg, measurement selection). Two individuals 
will contribute during the trial by reviewing participant 
information sheets, consent form, therapy workbooks 
and questionnaire measures. They will advise on recruit-
ment procedures and methods to engage prospective 
participants/retain enrolled participants. Finally they will 
support the dissemination of trial results through review 
of the final report to the funder, lay summary (which we 
will send to trial participants on completion of analysis) 
and media releases by the University of Oxford.
Ethics and dissemination
The trial has received both Health Research Authority 
approval (IRAS: 238138) and ethical approval (York-
shire and the Humber - Bradford Leeds Research Ethics 
Committee, reference: 18/YH/0153). We will publish our 
findings in high- impact, peer- reviewed journals. We will 
send trial participants a summary of study outcomes.
trial status
The trial commenced recruitment in August 2018 and 
will continue recruiting until approximately March 2020, 
with final outcome data expected around April 2021.
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